SummaryThe FDA has expanded approval of Addyi, a once-daily libido drug, allowing postmenopausal women over 65 to use it. The decision revives debate around hypoactive sexual desire disorder, the drug’s side effects, and how women’s sexual health is diagnosed and treated.